ALLO earnings date and last-quarter result: next report 2026-08-12, last quarter beat, P/E -2.42. Updated 2026-07-23.
Allogene Therapeutics (ALLO) Research Hub
Allogene Therapeutics (ALLO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.21 USD (-3.20%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.42, market cap 0.45B. This hub links to the full technical, earnings and options research available for ALLO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.21 USD (-3.20%) |
| 52-week range | 1.16 USD – 2.25 USD |
| Trend regime | Range |
| 14-day RSI | 26.4 (Oversold) |
| Trailing P/E | -2.42 |
| Market cap | 0.45B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for ALLO
Covered Call on ALLO: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALLO: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALLO: how it works, illustrative setup around the real 1.21 USD price, max profit/loss, breakeven and when to use it. Educational.
ALLO technical analysis: range, last 1.21 USD, RSI 26.4, 52w range 1.16 USD–2.25 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ALLO in?
Allogene Therapeutics (ALLO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ALLO in an uptrend or downtrend?
As of 2026-10-26, ALLO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALLO's trailing P/E ratio?
ALLO's trailing P/E is -2.42, with a market cap of 0.45B. See the earnings research page for full valuation detail.
When does ALLO next report earnings?
ALLO is next scheduled to report earnings on 2026-08-12.